Table 1.

Recent and Current Clinical Trials for Lupus Nphritis

DrugTrial StageTargetPhase/Status or MechanismReference/Clinical Trial Number
Completed Clinical Trials
 Abatacept – BMSCompleted clinical trialsCTLA4-B7 interactionPhase 3 – Failed to meet end point8
 Abatacept – ACCESSCompleted clinical trialsCTLA4-B7 interactionPhase 2 – Failed to meet end point15
 Anti-CD40LCompleted clinical trialsCD40-ligandPhase 2 – Terminated89
 Anti-TWEAKCompleted clinical trialsTWEAKPhase 2 – TerminatedNCT01499355
 BortezomibCompleted clinical trialsPlasma cellsPhase 4 – Terminated85
 LaquinamodCompleted clinical trialsInflammationPhase 2 – Encouraging101
 RituximabCompleted clinical trialsCD20Phase 3 – Failed to meet end point10
 OcrelizumabCompleted clinical trialsCD20Phase 3 – Failed to meet end point88
 SirukumabCompleted clinical trialsIL-6Phase 2 – Failed to meet end point102
 TabalumabCompleted clinical trialsB lymphocyte stimulatorPhase 3 – Failed to meet end point68
Active Clinical Trials
 AnifrolumabActive clinical trialsIFN-αPhase 2 – RecruitingNCT02547922
 BelimumabActive clinical trialsB lymphocyte stimulatorPhase 3 – Recruitment closedNCT01639339
 IxazomibActive clinical trialsPlasma cellsPhase 1 – RecruitingNCT02176486
 ObinutuzumabActive clinical trialsCD20Phase 2 – RecruitingNCT02550652
 RituximabActive clinical trialsCD20/steroid reducedPhase 3 – RecruitingNCT01773616
 Rituximab/BelimumabActive clinical trialsCD20/B lymphocyte stimulatorPhase 2 – RecruitingNCT02260934
 VoclosporinActive clinical trialsCalcineurinPhase 2 – Recruitment closedNCT02141672
Therapies for Consideration
 EculizumabTherapy for considerationC5Anti-inflammatory98
 Anti-C5aR (CCX168)Therapy for considerationC5aAnti-inflammatory103
 Anti–IL-17Therapy for considerationIL-17Anti-inflammatory104
  • BMS, Bristol-myers squibb; ACCESS, Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis.